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In numerous neurodegenerative diseases, the interplay between neurons and glia
modulates the outcome and progression of pathology. One particularly intriguing
mode of interaction between neurons, astrocytes, microglia, and oligodendrocytes is
characterized by the release of extracellular vesicles that transport proteins, lipids, and
nucleotides from one cell to another. Notably, several proteins that cause disease,
including the prion protein and mutant SOD1, have been detected in glia-derived
extracellular vesicles and observed to fuse with neurons and trigger pathology in vitro.
Here we review the structural and functional characterization of such extracellular vesicles
in neuron-glia interactions. Furthermore, we discuss possible mechanisms of extracellular
vesicle biogenesis and release from activated glia and microglia, and their effects on
neurons. Given that exosomes, the smallest type of extracellular vesicles, have been
reported to recognize specific cellular populations and act as carriers of very specialized
cargo, a thorough analysis of these vesicles may aid in their engineering in vitro and
targeted delivery in vivo, opening opportunities for therapeutics.
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INTRODUCTION
The central nervous system (CNS) is characterized by a reciprocal communication between
its diverse cellular populations. Neurons, the effector cells, interact with astrocytes, microglia,
oligodendrocytes and the vascular system to support their metabolic requests and respond to
environmental stimuli. Neurons communicate with each other to transmit signals at synapses
and release growth factors that influence the function and health of their targets. At the same
time they interact with astrocytes that sense and respond to neuronal activity and participate
to the re-uptake of neurotransmitters. Astrocytes also form end-foot processes, which constitute
the blood-brain barrier, and regulate nutrients delivery based on neuronal activity. Through the
capillaries, astrocytes sense external stimuli and can participate to the inflammatory response
upon activation of microglia, the resident immune cells of the CNS. In the last two decades,
numerous elegant papers established that the alteration of communication in the CNS is at the
base of several neurodegenerative conditions. In Amyotrophic Lateral Sclerosis (ALS), the genetic
removal of the mutant protein SOD1 in cell populations that are not usually vulnerable to the
disease, such as astrocytes and microglia, was sufficient to delay the progression of the symptoms
(Boillee et al., 2006; Yamanaka et al., 2008; Garden and La Spada, 2012). Accordingly, the expression
of α synuclein or mutant huntingtin or the prion protein in astrocytes was sufficient to enhance
neuronal vulnerability or induce disease (Ilieva et al., 2009). Finally, in Huntington’s disease the
sole expression of mutant huntingtin in cortical neurons, which are among the cells that dye during
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disease progression, is not sufficient to induce disease onset (Gu
et al., 2005), confirming again that the disease can be induced by
the interaction between different cell types.
One emerging mode of propagating such communication is
through the release of extracellular vesicles (EVs). EVs can be
divided into at least three types according to size and intracellular
origin (Table 1). The first type of EV, termed exosomes, are
small (50–200 nm) vesicles that are generated by the trafficking of
multivesicular bodies (MVBs) from the cytosol to the cell surface;
they are the most studied type of EV in terms of biogenesis and
are characterized by RNA and protein cargo. In contrast, the
second type of EV, termed microvesicles (MVs) or ectosomes
(100–1000 nm), are derived from the plasma membrane and are
released in response to specific stimuli, such as changes in ATP
levels (Colombo et al., 2014; Figure 1). Finally, the third kind of
EVs is called apoptotic bodies that are released during cell death
(500–2000 nm). Their role in cell communication has not been
explored so they will not be discussed further in this review.
In the central nervous system (CNS), all cell types have been
shown to release EVs that can either be taken up by neighboring
cells or released into the cerebrospinal fluid (CSF) and blood
(Colombo et al., 2012; Lugli et al., 2015). Although the function of
EV uptake by neighboring cells remains uncovered, the detection
of EVs in the CSF and plasma have raised the possibility that they
may be useful for early diagnosis in neurodegenerative diseases
(Colombo et al., 2012). Interestingly, pathogenic proteins such
as prions, amyloid β peptide, superoxide dismutase, α-synuclein,
and tau are released in association with EVs in a process that may
spread pathogenic proteins throughout the body (Coleman and
Hill, 2015). Genomic material has also been implicated in this
cell-to-cell communication; reports of RNA contained in EVs in
the CNS will be discussed along with EV biogenesis and release
in neuronal cells, as well as EV function under both physiological
and pathological conditions.
MICROVESICLES AND EXOSOMES:
DIFFERENT ORIGIN AND DIFFERENT
FUNCTION?
Although differentiated by size and biogenesis pathway, MVs
and exosomes share similar mechanisms of release and fusion
with recipient cells, as has been recently reviewed (Cocucci and
Meldolesi, 2015). MVs bud directly from the plasma membrane,
which blebs and packages the cellular components in defined
structures that are released into the extracellular environment
upon cell activation (Turola et al., 2012). MVs contain distinct
membrane regions of the cell of origin comprising receptors,
proteins, and genomic material. Because the content can vary
in different cell types or upon different stimuli, a major
challenge has been related to the identification of common
components of MVs that might enable their purification and
characterization. One of the best markers is the presence of
the lipid phosphatidylserine on the surface of MVs, which
determines their ability to target recipient cells (Frey and Gaipl,
2011). The mechanisms of MV biogenesis and release are
not completely understood in the CNS; several reports have
implicated the endosomal sorting complex required for transport
(ESCRT) pathway and ARF6 (Cocucci et al., 2009; Muralidharan-
Chari et al., 2009; Gan and Gould, 2011) in this process, similar
to exosomes. Interestingly, in cells expressing the purinergic
receptor P2X7, such as microglia, an increase in the extracellular
concentration of ATP induces the activation of the P2X7 receptor
and the release of MVs and it is possible to observe an immediate
pinching off of these vesicles from the plasma membrane (Bianco
et al., 2005; Cocucci et al., 2009; Cocucci and Meldolesi, 2015).
The transfer of MV cargo to recipient cells occurs via fusion
or endocytosis of the vesicles into their target cell, but the
mechanisms controlling the recognition of the target cell remain
under investigation (Figure 1).
In contrast, exosomes derive from the inward budding of
endosomal MVBs and are a more homogeneous population.
The intraluminal vesicles contained in the MVBs can be either
targeted to the lysosome or secreted as exosomes into the
extracellular space. Accordingly, lysosome inhibition correlates
with an increased release of α-synuclein from SH-SY5Y cells
(Alvarez-Erviti et al., 2011a). The activation of either of these
pathways is linked to the coordinated activity of the ESCRT
complex with other proteins such as ALIX, TGS101, synthenin,
and syndecan (Baietti et al., 2012). ESCRT is necessary to
ubiquitinate proteins and direct them to the MVBs. It has
been reported that silencing of early components of the
ESCRT machinery decreases exosome production and alters
their content (Colombo et al., 2013). Compelling evidence also
supports the enzyme sphingomyelinase and the production of
ceramide from raft-based microdomains rich in sphingolipids as
important components of the vesicle budding process. Ceramide
can self-associate through hydrogen bonding, thereby inducing
the coalescence of microscopic rafts into a large membrane
microdomain and facilitating exosome formation and release
(Trajkovic et al., 2008). Other molecules that facilitate fusion
of the MBV to the cell membrane are small GTPases such
as RAB27A, RAB11, and RAB35 (Colombo et al., 2014). This
is not surprising considering that Rab GTPase proteins are
important regulators of intracellular trafficking in secretory
pathways such as cargo selection in vesicle formation, vesicle
transport, tethering, and docking (Binotti et al., 2016). It has
been estimated that cells present specific sets of Rab proteins
that control biogenesis, maturation, transition, and interaction
of a subcellular organelle with other membranous compartments
(Stenmark, 2009). Rab11 is the first small GTPase associated
to exosome release (Savina et al., 2002). The overexpression
of a dominant-negative mutant Rab11S25N inhibited exosome
release suggesting a role of Rab11 in tethering and docking
of MVBs to plasma membrane (Savina et al., 2005). At the
same time, Rab11 has been recently observed in association with
α-synuclein and its knockdown or the overexpression of the
dominant negative form enhanced α-synuclein aggregation and
toxicity in a cell model of Parkinson’s disease (PD) (Chutna
et al., 2014). To have a broader view of all the Rabs involved
in exosome release, Ostrowski and colleagues used a small
hairpin (sh)RNA screen to reveal that Rab27A and Rab27B
where the two Rab GTPases controlling late endosome docking
and fusion to the plasma membrane in HeLa cells (Ostrowski
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TABLE 1 | Exosomes and MV main differences in biogenesis, properties, and functions.
Vesicle type Properties Biogenesis Function
Size Lipids
Exosomes 50–200 nm Ceramide Late endosome (MVB) Horizontal transmission of RNA and proteins
Microvesicles 50–1000 nm Phosphatydilserine Plasma membrane Horizontal Transmission of DNA and RNA
Apoptotic bodies 500–2000 nm Phosphatydilserine Plasma membrane Not yet reported
FIGURE 1 | Release and uptake of MVs and exosomes. Functional EVs are released through two different pathways; MVs bud directly from the plasma
membrane upon increase of extracellular ATP that opens the P2X7 receptor and allows the entrance of calcium. Their membrane is enriched in phosphatydil serine
and tetraspanins. Their cargo contains and cytoplasmic proteins, RNAs and DNAs. Exosomes are derived from the late endosome or multivesicular bodies (MVB)
where ESCRT coordinates the cargo loading and vesicle release. Rab GTPases, such as Rab27, 35, 11 and the SNARE protein YKY6 coordinate vesicle tethering
and fusion to the plasma membrane. The cargo content comprises proteins and RNAs like in MVs. The presence of DNA is highly debated. Exosomes can enter in
recipient cells trough endocytosis, ligand-receptor interaction (where both the ligand and the receptor are not clearly uncovered) or fusion with the plasma membrane.
et al., 2010; Figure 1). Interestingly, Rab27b participates in
synaptic vesicle exocytosis (Binotti et al., 2016) and in Drosophila
it is part of a hub of Rabs that controls synaptic functions
(Chan et al., 2011). Along this line, the inhibition of Rab35
leads to intracellular accumulation of endosomal vesicles and
impairs exosome secretion in oligodendrocytes. Rab35 localizes
to the surface of oligodendrocytes and plays a role in neurite
outgrowth (Chevallier et al., 2009; Kobayashi and Fukuda, 2012,
2013; Kobayashi et al., 2014; Etoh and Fukuda, 2015), possibly
mediated by its ability to control the release of exosomes as
discussed in the paragraph “Functional role of EVs_Regulation
of neuronal activity.” Other molecules that facilitate fusion of
the MBV to the cell membrane are SNARE (SNAP Soluble NSF
Attachment Protein Receptor) proteins like the YKT6 (Gross et
al., 2012) even if SNAREs have been little investigated in the EV
field (Colombo et al., 2014). Exosomes are usually released 10min
after the application of a specific stimulus, suggesting a delayed
process compared to the budding of microvesicles (Soo et al.,
2012; Cocucci and Meldolesi, 2015).
As is the case for MVs, the mechanisms determining
specificity of exosome transmission to the target cells are not
known, but the selectivity of neuronal exosomes to recognize
other neuronal cells has been clearly shown (Chivet et al., 2013).
Once exosomes are internalized into recipient cells, they can
either merge into endosomes and form new exosomes or be
degraded by the lysosome.
Both MVs and exosomes contain RNAs in the form of
mRNA and non-coding RNA that is transmitted from one
cell to the other. The important implication of horizontal
transfer of vesicular mRNA and miRNA is a direct effect on
epigenetic reprogramming of recipient cells or on the post-
transcriptional control of specific genes. Of note, a recent paper
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reported that transmitted RNA is non-functional in recipient
cells because it is degraded when released; instead plasmid DNA
could be transmitted from one cell to another (Kanada et al.,
2015). In line with this report, one recent study analyzed the
differences between the cargos of MVs and exosomes, suggesting
distinct functionalities (Keerthikumar et al., 2015b). Exosomes
were mostly enriched with receptors and kinases that mediate
signaling, whereas MVs presented centrosomal, ribosomal, and
mitochondrial proteins, implicating a functional role in protein
translation. An additional relevant difference concerns the
involvement of exosomes in antigen presentation and in the
transfer of both major histocompatibility complex molecules and
antigens (Chang et al., 2013), suggesting a functional role for
exosomes in immune regulation and in the interplay between
the CNS and the immune system. In sum, exosomes and MVs
can both deliver effector molecules such as proteins and RNAs
to target cells, but their functional roles, which we are only
beginning to appreciate, appear to be distinct.
Another aspect regards EV quantification that has proven
challenging due to the heterogeneity in the size and composition
of the population. The nanoparticle tracking analysis (NTA)
is one of the most frequently utilized (Soo et al., 2012).
NTA allows determining the mean size of the population of
vesicles analyzed and the particle concentration estimation in
the sample and can be paired to high-resolution flow cytometry
(Nolte-’T Hoen et al., 2012; Maas et al., 2015). These techniques
assess precisely the quality of the EV population, but not the
quantity (Maas et al., 2015). Therefore, it is still not known if
microvesicles and exosomes are differentially released in terms
of total amount. Accordingly, we cannot infer how much protein
is usually present per particle; for instance, the range is in the
low micrograms per 10ml of conditioned media derived from
HEK293 cells (Jeppesen et al., 2014), 80–90 µg from 3ml of
plasma (Bonetto, unpublished results). Regarding the nucleic
acid content, a detailed analysis has been performed in plasma of
cancer patients (Chevillet et al., 2014). Surprisingly, the analysis
revealed that there is on average only one copy of miRNA in each
vesicle. The stoichiometric model proposes that either miRNAs
may be distributed throughout the population of vesicles in a low
occupancy/low miRNA content ratio or in a low occupancy/high
miRNA concentration distribution. New experiments will be
needed to assert the amount of cargo contained in EVs in
vivo and their rate of release in physiological and pathological
conditions.
EV CARGOS IN THE CNS
Numerous targeted and omics studies have been carried out to
identify the constituents of EVs in multiple organisms and cell
types. Public online databases, such as ExoCarta (Mathivanan
and Simpson, 2009; Keerthikumar et al., 2015a), EVpedia (Kim
et al., 2015) and Vesiclepedia (Kalra et al., 2012), are available
to provide EV molecular data mainly for proteins and nucleic
acids, but also for lipids and metabolites. As of January 2015, the
databases have reported 218 studies on exosomes and 123 studies
on MVs (Vesiclepedia Version 3.1, release date January 2015).
Proteins
Several proteomics studies have highlighted a set of proteins that
are commonly found in exosome preparations (Table 2). These
are (i) transmembrane or lipid-bound extracellular proteins, such
as tetraspanins (e.g., CD9, CD63, CD81) and integrins (e.g.,
ITGB1); (ii) cytosolic proteins, such as endosomal or membrane
binding (e.g., TSG101, ANXA5, ANXA2, FLOT1, RAC1),
adapter (e.g., YWHAZ, YWHAE, SDCBP), and heat-shock (e.g.,
HSPA8, HSP90AA1) proteins; and (iii) extracellular proteins
binding specifically or non-specifically to EV membranes (e.g.,
A2M, ALB). Intracellular proteins associated with compartments
such as endoplasmic reticulum, nucleus, and mitochondria are
absent or under-represented in exosomes, but may be present in
other EVs (Lotvall et al., 2014; Keerthikumar et al., 2015b). EV
loading is thought to be an active process controlled through
a variety of pathways, ESCRT-dependent and independent,
most of which are still not fully understood (Villarroya-Beltri
et al., 2013a, 2014). In fact, EVs are enriched in specific
proteins, lipids and RNAs. However, the most commonly found
proteins in EVs (Table 2), excluding the ones associated with
the membrane/vesicle trafficking, are also the most abundant
proteins of the cell (highest protein copies per cell; Beck et al.,
2011), arguing that a sorting process is applied to all cargos.
The relative proportions of the different proteins appear to vary
depending on conditions and types of EVs (Keerthikumar et al.,
2015b). One recent proteomic study compared exosomes and
MVs from neuroblastoma cell lines and identified candidate
protein markers that might aid in discriminating between them:
VPS24, VPS32, VPS36, CD81, TSPAN9, TSPAN14, ANXA7,
synthenin, and ITGA3 in exosomes and RACGAP1, PDIA3,
SPTBN2, MUC19, UBR4, KRT18, KIF14, KIF4A, VIM, RPS9,
RPS18, and MMP2 in MVs (Keerthikumar et al., 2015b).
However, since exosomes and MVs are physically very similar,
results with purified vesicles using current technologies have
yet to be considered with caution. Notably, most studies use
EVs generated by endothelial cells, stem cells, or tumor cells
because neuronal cells generally release low amounts of EVs,
and are difficult to detect based on current technologies. Unique
proteins that reflect the specialized function of the cells of origin
have been identified; for example, myelin proteins have been
found in EVs from oligodendrocytes (Kramer-Albers et al., 2007).
Other studies have examined EVs in the context of disease,
identifying microglia-derived EVs in the CSF of patients with
multiple sclerosis using isolectin B4 labeling (Verderio et al.,
2012). Neurofilament proteins (namely NEFL and NEFM) have
been found in EVs isolated from human CSF (Chiasserini
et al., 2014). However, true cell-specific markers have not yet
been identified, despite their clear utility in understanding the
contribution and impact of the different types of EVs in the
CNS.
Most studies of EVs in the CNS have examined EVs isolated
from cultured cell media (e.g., neurons, astrocytes, microglia,
and oligodendrocytes); very few have used CSF samples. Among
these studies, Vella et al. first identified the prion protein in
EVs from ovine CSF (Vella et al., 2008a). Later proteomic
analyses of EVs isolated from human CSF provided limited
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TABLE 2 | List of the top 50 most commonly identified proteins in exosome preparations.
Protein name Gene Timesa Function
1 CD9 antigen CD9 98 Integral membrane protein
2 Heat shock cognate 71 kDa protein* HSPA8 96 Protein folding
3 Programmed cell death 6 interacting protein PDCD6IP 96 Adapter in vesicle trafficking
4 Glyceraldehyde-3-phosphate dehydrogenase* GAPDH 95 Glycolysis
5 Actin, beta* ACTB 93 Cytoskeletal
6 Annexin A2* ANXA2 83 Vesicle trafficking
7 CD63 antigen CD63 82 Integral membrane protein
8 Syntenin-1 SDCBP 78 Protein membrane scaffolding
9 Alpha-enolase* ENO1 78 Glycolysis
10 Heat shock protein HSP 90-alpha* HSP90AA1 77 Protein folding
11 Tumor susceptibility gene 101 protein TSG101 75 Vesicle trafficking
12 Pyruvate kinase PKM* PKM 72 Glycolysis
13 L-lactate dehydrogenase A chain* LDHA 72 Glycolysis/ Krebs cycle
14 Elongation factor 1-alpha 1* EEF1A1 71 Translation
15 14-3-3 protein zeta/delta* YWHAZ 69 Adapter in signaling
16 Phosphoglycerate kinase 1* PGK1 69 Glycolysis
17 Eukaryotic elongation factor 2 kinase* EEF2 69 Translation
18 Fructose-bisphosphate aldolase A* ALDOA 69 Glycolysis
19 Heat shock protein 90kDa alpha class B member 1* HSP90AB1 67 Protein folding
20 Annexin A5* ANXA5 67 Vesicle trafficking
21 Fatty acid synthase FASN 66 Fatty acid biosynthesis
22 14-3-3 protein epsilon* YWHAE 65 Adapter in signaling
23 Clathrin heavy chain 1 CLTC 64 Component of coated vesicles
24 CD81 antigen CD81 64 Integral membrane protein
25 Serum albumin ALB 63 Extracellular (aspecific binding?)
26 Valosin-containing protein* VCP 62 Protein degradation
27 Triosephosphate isomerase* TPI1 62 Glycolysis
28 Peptidylprolyl isomerase A (cyclophilin A) * PPIA 62 Protein folding
29 Moesin* MSN 62 Cytoskeletal
30 Cofilin-1* CFL1 62 Cytoskeletal
31 Peroxiredoxin-1* PRDX1 61 Redox regulation
32 Profilin-1* PFN1 61 Cytoskeletal
33 Ras-related protein Rap-1b RAP1B 60 Small GTPase
34 Integrin, beta-1 ITGB1 60 Integral membrane protein
35 78 kDa glucose-regulated protein HSPA5 58 Protein folding
36 4F2 cell-surface antigen heavy chain SLC3A2 57 Integral membrane protein
37 Histone H4* HIST1H4A 57 DNA binding
38 Guanine nucleotide-binding protein, beta 2* GNB2 57 Small GTPase
39 Sodium/potassium-transporting ATPase alpha-1 ATP1A1 57 Metabolic process
40 14-3-3 protein theta* YWHAQ 56 Adapter in signaling
41 Flotillin-1 FLOT1 56 Vesicle trafficking
42 Filamin-A FLNA 56 Cytoskeletal
43 Chloride intracellular channel protein 1* CLIC1 56 Ion channel
44 T-complex protein 1 subunit beta* CCT2 56 Protein folding
45 CDC42 small effector protein 1 CDC42 55 Small GTPase
46 14-3-3 protein gamma YWHAG 54 Adapter in signaling
47 Alpha-2-macroglobulin A2M 54 Extracellular (aspecific binding?)
48 Tubulin alpha-1B chain* TUBA1B 53 Cytoskeletal
49 Ras-related C3 botulinum toxin substrate 1 RAC1 53 Small GTPase
50 Galectin-3-binding protein LGALS3BP 53 Cell adhesion
aNumber of times identified in the studies collected by the Exocarta database (Mathivanan and Simpson, 2009; Keerthikumar et al., 2015a), release date 29 July 2015; proteins indicated
in bold are often used as exosome markers. *Very abundant proteins in human cells [protein copies per cell > 100 × 106 (Beck et al., 2011)].
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information (Harrington et al., 2009; Street et al., 2012). More
recently, Chiasserini et al. applied high resolution MS/MS-based
proteomics to the analysis of EVs isolated from pooled samples
of CSF and built a dataset of proteins that provide a basis for
biomarker studies in neurological diseases (Chiasserini et al.,
2014). Interestingly, EVs contain several proteins that have
relevance to CNS disease, including all major neuropathological
hallmarks of neurodegenerative diseases, such as amyloid β
peptide and tau/phosphorylated tau for Alzheimer’s disease
(AD), α-synuclein for PD, and SOD1/mutant SOD1 and TDP-
43 for amyotrophic lateral sclerosis (ALS) (Table 3). The reason
for this it has not yet been understood. We can hypothesize
that cells use EV secretion as an alternative pathway to
remove aggregate-prone pathological proteins when the protein
clearing system is dysfunctional, which is a common feature of
neurodegenerative diseases. For example we reported increased
exosome secretion in astrocytes expressing mutant SOD1 (Basso
et al., 2013), which is known to escape the cell degradation
machinery and impair the proteasomal system and autophagy
in experimental models of ALS (Bendotti et al., 2012; Chen S.
et al., 2012). Moreover, secretion of toxic α-synuclein oligomers
via exosomes is strongly influenced by autophagic activity, with
enhanced release with an autophagic inhibitor and decrease
release with an autophagic enhancer (Danzer et al., 2012). It is
also possible that aggregation or higher-order oligomerization
act as a general sorting signal to target certain proteins into
EVs providing an effective means for clearing damaged and
potentially toxic proteins from the cells (Vidal et al., 1997; Fang
et al., 2007).
The findings that misfolded/aggregated proteins can be
secreted through EVs have made these vesicles extremely
attractive as a source of biomarkers for neurodegenerative
diseases, with relevant publications recently emerging from
studies of peripheral biofluids (Shi et al., 2014; Fiandaca
et al., 2015; Goetzl et al., 2015; Tomlinson et al., 2015).
Although the fraction of CNS-specific EVs is likely limited in
peripheral biofluids, peripheral EV protein biomarkers could
be useful to monitor systemic alterations that reflect CNS
alterations and at the same time impact CNS function, as was
previously demonstrated with peripheral blood mononuclear cell
protein biomarkers in ALS (Nardo et al., 2011). Interestingly,
several proteins, including VCP and PPIA, which have been
associated with ALS and frontotemporal lobar degeneration
(Johnson et al., 2010; Lauranzano et al., 2015) are among
the most commonly identified proteins in EVs (Table 3).
These proteins are present in both exosomes and MVs from
neurons, glial cells, and human CSF; however, no reports have
demonstrated the functional implications of these common
proteins being released in EVs. Other EV proteins causally
linked to neurodegenerative diseases include APOE (AD),
ANG, PFN1, HNRNPA1, and TUBA4A (ALS), and PARK7
(PD; Table 3). EVs can also contain proteins that play roles
in neuroprotection (e.g., VEGF, SYN, and CP), neuronal
function (e.g., EAAT1, GRIA2-4), neuroinflammatory response
(e.g., MMP2, MMP9 and IL1B), and apoptosis (e.g., PAR4;
Table 3).
Nucleic Acids
The first report of RNA in EVs (Valadi et al., 2007) opened a
new perspective in the field, suggesting that not only proteins
but also genomic material (namely mRNA and miRNA) could
be exchanged between cells. MiRNAs are a class of small
RNA molecules that regulate gene expression by binding to
mRNAs and triggering their degradation or inhibiting their
translation. Considering that miRNAs can control the expression
ofmultiple mRNAs, it is believed that the horizontal transmission
of miRNAs through EVs play a functional role in intercellular
communication (Chen X. et al., 2012; Ramachandran and
Palanisamy, 2012). An additional interest was the possibility of
using EV-derived small non-coding RNAs as novel biomarkers
for neurodegeneration (Rao et al., 2013), as EVs can be recovered
not only from CSF but also from peripheral sources such
as blood and urine. Further studies, reviewed in (Rao et al.,
2013), showed that plasma exosomes contained RNA derived
from neuronal cells, potentially mirroring the activities of the
CNS and offering the opportunity for non-invasive analysis.
At the same time, these studies shed light on several technical
challenges related to the observation that different extraction
techniques of similar samples could lead to diverse miRNA
detection. To minimize the incongruence between different
laboratories, the International Society of Extracellular Vesicles
published guidelines and gold standard protocols that should
be followed when working with EVs (Lotvall et al., 2014).
To date, a plethora of small non-coding RNAs have been
observed in EVs, including vault RNA, Y-RNA, piwi RNA, small
nucleolar RNA, small nuclear RNA, and tRNA, although there
appears to be preferential sorting for selected miRNAs (Janas
et al., 2015). This sorting may be controlled by the affinity
between miRNAs and specific RNA-binding proteins that deliver
them to the raft-like region of the MVB limiting membrane.
In particular, the protein heterogeneous nuclear riboprotein
A2B1 (hnRNP2AB1) recognizes and binds specific RNA motifs
in miRNAs (called EXOmotifs, Table 4) and controls their
sorting into exosomes when sumoylated (Villarroya-Beltri et al.,
2013b). Interestingly, hnRNPA2B1 is involved in RNA trafficking
in neurons (Carson and Barbarese, 2005), and mutations in
hnRNPA2B1 cause a multisystem proteinopathy called inclusion
body myopathy with Paget disease and frontotemporal dementia
(Kim et al., 2013). Furthermore, hnRNPA2B1 interacts with
another RNA-binding protein, TDP-43, whose presence in
protein inclusions is a hallmark of ALS and frontotemporal
dementia, and with PPIA, a biomarker of ALS and a key
regulator of TDP-43 function (Nardo et al., 2011; Lauranzano
et al., 2015). Another observation confirming that specific
miRNAs are loaded in EVs comes from the comparative
analysis of miRNAs contained in EVs derived from HEK293T
cells, mesenchymal stem cells, macrophages, and immune
cells, showing that miR-451 is one of the most commonly
released miRNAs across all different sources (Guduric-Fuchs
et al., 2012). MiR-451 controls nine genes, including MYC and
AKT, and is increased in neuronal tissues of mice that have
undergone traumatic brain injury (Meissner et al., 2015) and
downregulated in neuronal cells treated with the antioxidant
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TABLE 3 | A selection of proteins identified in EVs isolated from cultured cell media (neurons, astrocytes, microglia, oligodendrocytes) and CSF that are
relevant for the CNS under physiological and pathological conditions.
Gene Protein name Na Ab Mc Od CSF Referencese
ANG Angiogenin X Chiasserini et al., 2014
APOE Apolipoprotein E X X Harrington et al., 2009; Marimpietri et al., 2013
APP Amyloid beta A4 protein X X X Rajendran et al., 2006; Harrington et al., 2009; Joshi et al.,
2014
CD13 Aminopeptidase N X Potolicchio et al., 2005
CP Ceruloplasmin X X Faure et al., 2006; Chiasserini et al., 2014
CNP 2′,3′-cyclic-nucleotide 3’-phosphodiesterase X X X Kramer-Albers et al., 2007; Marimpietri et al., 2013; Chiasserini
et al., 2014
EAAT1 Excitatory amino acid transporter 1 X Faure et al., 2006
GRIA2 Glutamate receptor 2 X Faure et al., 2006
GRIA3 Glutamate receptor 3 X Faure et al., 2006
GRIA4 Glutamate receptor 4 X Chiasserini et al., 2014
HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 X Chiasserini et al., 2014; Keerthikumar et al., 2015a
IL1B Interleukin-1 beta X Bianco et al., 2005
MBP Myelin basic protein X X Kramer-Albers et al., 2007; Chiasserini et al., 2014
MCT1 Monocarboxylate transporter 1 X X Potolicchio et al., 2005; Marimpietri et al., 2013
MMP2 Matrix metallopeptidase-2 X X Sbai et al., 2010; Chiasserini et al., 2014
MMP9 Matrix metallopeptidase-9 X Sbai et al., 2010
MOG Myelin oligodendrocyte glycoprotein X X Kramer-Albers et al., 2007; Chiasserini et al., 2014
NEFL Neurofilament light polypeptide X Chiasserini et al., 2014
NEFM Neurofilament medium polypeptide X Harrington et al., 2009
PAR4 Prostate apoptosis response 4 protein (PAR-4) X Wang et al., 2012
PARK7 Protein deglycase DJ-1 X Chiasserini et al., 2014
PFN1 Profilin-1 X Chiasserini et al., 2014
PLP1 Myelin proteolipid protein X X Kramer-Albers et al., 2007; Chiasserini et al., 2014
PPIA Peptidyl-prolyl cis-trans isomerase A (Cyclophilin A) X Xf X X X Potolicchio et al., 2005; Faure et al., 2006; Kramer-Albers et al.,
2007; Chiasserini et al., 2014
PRNP Prion protein X X Faure et al., 2006; Vella et al., 2008a
SOD1 Superoxide dismutase [Cu-Zn] Xg Xg X Gomes et al., 2007; Basso et al., 2013; Chiasserini et al., 2014
SNCA Alpha-synuclein X Emmanouilidou et al., 2010
SYN1 Synapsin-1 X X Wang et al., 2011; Chiasserini et al., 2014
MAPT Microtubule-associated protein tau Xh X Xi Saman et al., 2012; Asai et al., 2015
TARDBP TAR DNA-binding protein 43 (TDP-43) X Nonaka et al., 2013
TUBA4A Tubulin alpha-4A chain X X Chiasserini et al., 2014; Keerthikumar et al., 2015a
VCP Valosin-containing protein X X X Basso et al., 2013; Chiasserini et al., 2014; Keerthikumar et al.,
2015a
VEGFA Vascular endothelial growth factor A X X Schiera et al., 2007; Proia et al., 2008
aN, neuronal cells (primary cultures or cell lines).
bA, astrocytes.
cM, microglia.
dO, oligodendrocytes.
eReferences, the first published evidence.
fUnpublished evidence.
gDetected wild-type and mutant SOD1.
hDetected tau and phosphorylated tau.
iDetected only phosphorylated tau.
EPO (Alural et al., 2014), suggesting that its secretion via
EVs could be important in acute damage. Other properties
that determine the selective loading of miRNA cargo are
related to the presence of a lipid-bilayer binding motif within
the RNA sequence and RNA hydrophobic modifications that
facilitate RNA binding to the EV membrane (Janas and Yarus,
2006).
The miRNAs released in EVs are functional and activate
specific signals in target cells, as in the case of miR-124a, which
is transferred from neurons to astrocytes and regulates the levels
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TABLE 4 | EXOMotifs. Specific RNA motifs recognized by hnRNPA2B1 for
cargo loading in EVs.
RNA Motif
1 GGAG
2 UGAG
3 UGCG
4 UGGG
5 UGAC
6 UGCC
7 UGGC
8 GGCG
9 GGGG
10 GGAC
11 GGGG
12 GGCC
13 GGGC
14 CCCU
15 CCCG
16 CCCA
17 UCCU
18 UCCG
19 UCCA
20 GCCU
21 GCCG
22 GCCA
of the excitatory amino acid transporter 2, important in synaptic
modulation (Morel et al., 2013). Another interesting example is
the release of EVs rich in miRNAs during synaptic depolarization
that leads to a local decrease of miRNAs at the synaptic cleft and
a global reduction in postsynaptic gene silencing to facilitate a
rapid increase in local translation (Goldie et al., 2014).
To date, few studies have been performed in neurons
to identify exosomal non-coding RNAs, and reports are still
lacking regarding the potential identification of biomarkers
for neurodegenerative diseases. One pilot study of EV-derived
miRNAs purified from cells infected with the prion protein
reported an increase in the release of several miRNAs such as
let-7b, miR-146a, miR-103, miR-125a-5p, miR-342-3p also shown
to be dysregulated in human samples obtained from patients
affected by the prion disease (Bellingham et al., 2012). Of note,
it has been recently estimated that only a small percentage of
exosomes contain miRNAs, supporting the hypothesis that only
specific exosomes carry a full load of miRNAs and transport them
to selected targets (Chevillet et al., 2014).
FUNCTIONAL ROLES OF EVS
The identification of EV cargos is essential to understand the
biological relevance of this system in the CNS, but such studies
must be paired with investigations into functional roles for EVs.
In this regard, numerous observations have been reported in
several aspects of neuronal biology ranging from development
to degeneration. Here we discuss the most recent observations
regarding the role of EVs in synaptic activity and in physiological
and pathological conditions, with a final discussion of the
most recent technologies developed to address this important
question.
Regulation of Neuronal Activity
The first evidence of a functional role for EVs in the CNS was
obtained in vitro, in which EVs were shown to contribute to
the modulation of the synaptic activity. Initial studies reported
that the release of EVs increased when neurons were depolarized
with KCl (Faure et al., 2006) or treated with bicullin, an agonist
of GABAA receptors (Lachenal et al., 2011). Neuronal exosomes
carry glutamate receptor (GluR2) subunits and are thought
to participate in synaptic plasticity, regulating the amount of
postsynaptic AMPA andNMDA receptors. Notably, a subsequent
paper from the same group reported that exosomes released
by neurons were able to recognize their target cells, suggesting
that these released vesicles likely play a specific function (Chivet
et al., 2013). For instance, exosomal synaptotagmin 4 is released
by presynaptic terminals and transmitted to postsynaptic cells,
activating retrograde signaling and synaptic growth (Korkut
et al., 2013). At the same time, exosomes derived from
oligodendrocytes can also be internalized by neurons at axonal
and somatodendritic sites and can protect neurons from insults
(Fruhbeis et al., 2013) by inducing the transcription of genes
involved in the neuronal antioxidant response, such as catalase
and superoxide dismutase (Fröhlich et al., 2014). Interestingly,
neuronal activity appears to be necessary to induce the exchange
of EVs, given the observation that calcium chelation at the
synaptic cleft or inhibition of NMDA receptors is sufficient to
fully abrogate exosome release (Fruhbeis et al., 2013). Microglia
can also participate in the modulation of synaptic activity via
MVs (Antonucci et al., 2012). MVs that are released from
microglia interact with the neuronal plasma membrane and
enhance spontaneous and evoked excitatory transmission by
inducing sphingolipid metabolism in neurons (Antonucci et al.,
2012); the increase in ceramide upregulates glutamate secretion
in culture and initiates synaptic activity. Similarly, transport
of endocannabinoids via MVs stimulates type 1 cannabinoid
receptors and inhibits presynaptic transmission in GABAergic
neurons (Gabrielli et al., 2015).
Astrocytes are also involved in the release of EVs and in
modulation of synaptic activity. Astrocytes scavenge extracellular
glutamate through membrane excitatory amino acid transporters
(EAAT-1 and EAAT-2) in a process that is essential for
neurotransmission. Accordingly, loss of glutamate homeostasis
has been linked to neurodegeneration (Kim et al., 2011). The
astrocyte glutamate transporters EAAT-1 and EAAT-2 have been
identified in EVs upon activation of protein kinase C, which
normally controls their subcellular localization (Gosselin et al.,
2013); however, a direct role in synapse modulation remains to
be established. Neurons also control their own synaptic activity
and dendrite growth through the release of EVs that contain
specific miRNAs that locally regulate protein translation (Goldie
et al., 2014) or induce the expression of the EAAT-2 in astrocytes;
specifically, miR-124 is released by neurons and can modulate
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the expression of EAAT-2 in neighboring astrocytes (Morel et al.,
2013).
Involvement in Neurodegenerative
Processes: EV and the Prion-Like
Hypothesis of Neurodegenerative Diseases
The prion protein was the first protein to be detected in exosomes
of ovine CSF infected by prion disease (Vella et al., 2008a),
followed by phosphorylated tau (Saman et al., 2012) and amyloid
β in models of AD (Yuyama et al., 2015) and α-synuclein in
patients with PD (Shi et al., 2014; Yang et al., 2015). Notably,
all of these proteins have shown a propensity to assume a prion-
like behavior of changing the conformation of other proteins in
tissue and propagate disease (Ghidoni et al., 2008; Coleman and
Hill, 2015). Accordingly, the injection of exosomes containing
prions induced prion propagation in wild-type recipient cells
and induced prion disease when inoculated into mice (Fevrier
et al., 2004; Vella et al., 2007, 2008b). Similar EV toxicity
was reported for α-synuclein in PD (Emmanouilidou et al.,
2010) and for mutant SOD1 (Basso et al., 2013; Grad et al.,
2014) and TDP-43 (Ding et al., 2015) in ALS. Nevertheless, it
is important to consider that definitive studies regarding the
necessity and sufficiency of the mutant proteins in EVs for the
onset of neurodegeneration have not been reported; indeed, other
cargos, such as metabolites, proteins, or RNAs could play a
primary role in the propagation of pathology. Consistent with
this concept, the reduction of exosome release by inhibition of
neutral sphingomyelinase 2 by GW4869 in an in vivo model of
AD lowered the amount of amyloid β plaques observed in brain
sections (Dinkins et al., 2014). The same treatment also proved
to be effective in another in vivo AD model, characterized by
the spreading of aggregated tau from the entorhinal cortex to the
hippocampal region; in this study, the authors demonstrated that
aggregated tau was phagocytosed by microglia and released in
EVs. The depletion of microglia or inhibition of EV release was
sufficient to halt the spreading of the disease (Asai et al., 2015).
Similarly, exosomes purified from astrocytes expressing mutant
SOD1 were sufficient to induce motor neuron death (Basso et al.,
2013). This may indicate that glial cells that in normal conditions
are secreting trophic and protective factors for neurons, under
pathological conditions are changing their phenotype and
contribute to spreading and toxicity trough EV secretion. It
would be interesting to test whether this happens also with
oligodendrocytes and in different models of neurodegenerative
diseases. Indeed EVs purified from other sources have also
showed protective effects. For example, exosomes derived from
N2a cells and injected intracerebroventricularly in the APPSweInd
model of AD reduced amyloid β levels, amyloid deposition, and
amyloid β-mediated synaptotoxicity in the hippocampus. This
beneficial effect correlated with an increase in glycosphingolipids
in exosomes, essential to scavenge amyloid β extracellularly and
facilitate its clearance (Yuyama et al., 2014). An additional study
reported that exosomes purified from the plasma of PD patients
were internalized into primary neuronal cultures and could
protect neurons exposed to toxic stimuli (Tomlinson et al., 2015).
Considering these data, caution must be used in interpreting the
protective or pathogenic effects of EVs in neurodegeneration.
Establishment of New Tools to Test EV
Functionality In vivo
Themost significant promise of EVs is their potential therapeutic
application. EVs are stable in the blood and can therefore
be injected into the body, cross the blood-brain barrier, and
reach their targets. Ideally, it might be possible to induce the
production of massive amounts of EVs from specific cells,
purify them, and introduce particular molecules such as siRNAs
(El-Andaloussi et al., 2012), anti-miRs, or lipids (Yuyama
et al., 2014) to restore the lipid dyshomeostasis that is typical
of neurodegenerative conditions. Elegant strategies have been
developed to monitor EVs in vivo. One recent paper (Wiklander
et al., 2015) characterized the biodistribution of EVs in mice
after systemic delivery. In this study, EVs were isolated from
three different mouse cell sources and labeled with a lipophilic
dye, demonstrating that the origin of the cells and the route of
administration, along the dose of injected EVs, influenced the
biodistribution pattern. For example, EVs derived from dendritic
cells preferentially accumulated in the spleen, and the best route
of delivery for the spleen was intravenous injection. Notably, the
specific delivery of EVs to the CNS required the presence of an
RVG peptide, derived from the acetylcholine receptor, on the EV
membrane. The use of these engineered EVs led to the effective
silencing of BACE1, an approach that has therapeutic promise
in AD (Alvarez-Erviti et al., 2011b), or silencing of α-synuclein,
which reduced the formation of intracellular inclusions in an in
vivomodel of PD (Cooper et al., 2014).
An additional compelling tool to allow in vivo tracking is
the labeling of EVs with Gaussia luciferase for noninvasive
bioluminescence imaging (Lai et al., 2014b). In one recent study,
EVs were engineered to display a membrane reporter, termed
EV-GlucB, consisting of Gaussia luciferase fused with a biotin
acceptor domain, which is biotinylated in vivo by biotin ligases.
The luciferase is revealed after administration of the substrate and
monitored with in vivo bioluminescence imaging technology. At
the same time, biotin on the EV surface can be conjugated to
labeled streptavidin and imaged with several techniques such as
fluorescence-mediated tomography (Lai et al., 2014a). Such new
technologies will be particularly useful as researchers move into
more translational areas of EV research.
FUTURE PERSPECTIVES
The field of EVs is continuously growing and has generated
significant excitement, as testified by the recent exponential
increase in the number of EV-related publications. The
involvement of EVs in the modulation of synaptic activity, as well
as their functional roles in the spreading of neurodegenerative
diseases, highlight the importance of studying and understanding
how to engineer EVs to counteract their toxic effects. Additional
studies are necessary to uncover the mechanisms leading to EV
formation in the CNS. Although ceramide and sphingomyelinase
2 are certainly playing an important role in EV formation,
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it is unlikely that they can orchestrate the choice of cargo.
ESCRT also appears to be important for exosome formation;
notably, ESCRT dysfunction along with aberrant endosomal
trafficking and improper ubiquitination and deubiquitination
are related to neurodegeneration. STAM1, HRS, and AMSH,
three proteins of the ESCRT complex, induce neuronal loss
in the hippocampus when knocked out in mice. Knockout
mice for STAM1/STAM2 and UBPY, other ESCRT proteins, are
embryonic lethal (Kapuralin et al., 2015).
Another open question relates to the specificity of EV cargos
in the CNS. In this regard, only a thorough characterization
of their contents, including the metabolites and lipids that are
not typically analyzed, will help to define EV functions. Other
unresolved questions relate to the characterization of the proteins
localized on the extracellular membrane of EVs that serve as
receptors and mediate the recognition of the correct target cell.
EVs have also the potential to identify specific biomarkers
in the CNS to monitor the outcome of neurodegenerative
conditions. Given their relatively stable biophysical properties,
EVs released by the CNS, muscles, or other cells affected by
disease can readily circulate through the body and be found
in biological fluids, including blood (Verderio et al., 2012).
As the generation and release of EVs can be an extremely
rapid cellular process, reflecting dynamic cellular states and
eventually specific disease stages, EVs have great potential to
report on disease progression with high sensitivity and specificity.
In particular, plasma concentration of exosomes and their
biochemical properties may be useful parameters, although these
must be verified in clinically well-characterized longitudinal
cohorts of patients and controls with the aim of identifying a
reliable fingerprint of disease progression. Biomarkers for disease
progression could shorten the duration of clinical trials, reducing
the cost and time necessary to bring important therapies to
patients.
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